Literature DB >> 11850841

Preferential loss of Death Associated Protein kinase expression in invasive pituitary tumours is associated with either CpG island methylation or homozygous deletion.

D J Simpson1, R N Clayton, W E Farrell.   

Abstract

Death Associated Protein kinase (DAP kinase) a novel calmodulin-dependent serine/threonine kinase was first identified as a positive mediator of programmed cell death. Loss of DAP kinase expression was first demonstrated in highly metastatic cells, whilst re-expression of the protein resulted in delayed local tumour growth and a decreased incidence of metastasis. Although loss of DAP kinase expression has been reported in several cell lines derived from human malignancies the mechanisms responsible have not been defined. In this study we have examined 32 sporadic pituitary tumours for expression of the DAP kinase protein and transcript. In addition, we examined the methylation and deletion status of the DAP kinase CpG island as possible mechanisms for the inactivation of the DAP kinase gene. Eleven of 32 (34%) tumours had undetectable DAP kinase expression, by Western blot and/or RT-PCR analysis. Loss of DAP kinase expression was significantly (P=0.004) associated with invasive tumours (10 of 17; 59%) compared to their non-invasive (1 of 15; 7%) counterparts. Of 11 tumours that failed to express DAP kinase, five (45%) showed de novo methylation of the CpG island contained within the promoter region, while four (36%) had evidence of homozygous deletion of this region. Statistical analysis showed that loss of DAP kinase expression was significantly (P=<0.001) associated with methylation or deletion of the DAP kinase CpG island. With two exceptions, none of the remaining tumours or five histologically normal post-mortem pituitaries examined had evidence of methylation or deletion within this region. To our knowledge this is the first report that describes two mutually exclusive mechanisms associated with loss of DAP kinase gene expression. In addition, we also show that loss of the DAP kinase protein and associated genetic aberrations preferentially segregates with tumours that show an invasive phenotype.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11850841     DOI: 10.1038/sj.onc.1205195

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  21 in total

1.  Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.

Authors:  Katharina H Ruebel; Alexey A Leontovich; Long Jin; Gail A Stilling; Heyu Zhang; Xiang Qian; Nobuki Nakamura; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

Review 2.  [Role of transcription factor AP-1 in integration of cellular signalling systems].

Authors:  K T Turpaev
Journal:  Mol Biol (Mosk)       Date:  2006 Nov-Dec

Review 3.  Familial isolated pituitary adenomas: from genetics to therapy.

Authors:  Federica Guaraldi; Roberto Salvatori
Journal:  Clin Transl Sci       Date:  2011-02       Impact factor: 4.689

Review 4.  Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications.

Authors:  Keishi Yamashita; Shinichi Sakuramoto; Masahiko Watanabe
Journal:  Surg Today       Date:  2010-12-30       Impact factor: 2.549

5.  Death-associated Protein Kinase-1 Expression and Autophagy in Chronic Lymphocytic Leukemia Are Dependent on Activating Transcription Factor-6 and CCAAT/Enhancer-binding Protein-β.

Authors:  Padmaja Gade; Amy S Kimball; Angela C DiNardo; Priyamvada Gangwal; Douglas D Ross; H Scott Boswell; Susan K Keay; Dhananjaya V Kalvakolanu
Journal:  J Biol Chem       Date:  2016-09-02       Impact factor: 5.157

Review 6.  The pituitary tumour epigenome: aberrations and prospects for targeted therapy.

Authors:  Kiren Yacqub-Usman; Alan Richardson; Cuong V Duong; Richard N Clayton; William E Farrell
Journal:  Nat Rev Endocrinol       Date:  2012-04-24       Impact factor: 43.330

7.  DNA methylation in promoter region as biomarkers in prostate cancer.

Authors:  Mihi Yang; Jong Y Park
Journal:  Methods Mol Biol       Date:  2012

Review 8.  Deregulated chromatin remodeling in the pathobiology of brain tumors.

Authors:  Anastasia Spyropoulou; Christina Piperi; Christos Adamopoulos; Athanasios G Papavassiliou
Journal:  Neuromolecular Med       Date:  2013-03       Impact factor: 3.843

9.  Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data.

Authors:  Hui-Juan Yang; Vincent W S Liu; Yue Wang; Percy C K Tsang; Hextan Y S Ngan
Journal:  BMC Cancer       Date:  2006-08-23       Impact factor: 4.430

10.  Integrated multi-omics profiling of nonfunctioning pituitary adenomas.

Authors:  Zhenqing Wei; Cuiqi Zhou; Minghui Li; Ruocheng Huang; Hongjuan Deng; Stephen Shen; Renzhi Wang
Journal:  Pituitary       Date:  2020-11-18       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.